Skip to content
Clinical Trials – home
Therapeutic area

Immune system disorders – page 45

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Study on Pioglitazone for Improving Kidney Health in Patients with ANCA-Associated Vasculitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexchlorpheniramine
  • Sponsor:Assistance Publique Hopitaux De Paris

Asthma

Recruiting

Study on the Effectiveness and Safety of Indacaterol Acetate/Mometasone Furoate vs. Budesonide for Children Aged 6-11 with Asthma

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Budesonide
  • Sponsor:Novartis Pharma AG

Psoriasis

Recruiting

Study on Deucravacitinib for Children with Moderate to Severe Plaque Psoriasis

Investigational
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Effectiveness of Eltrombopag in Combination with Other Drugs for Patients with Immune Thrombocytopenia

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Avatrombopag
  • Sponsor:Fakultni Nemocnice Hradec Kralove

Study on the Impact of Dapagliflozin on Quality of Life and Exercise Capacity in Patients with Transthyretin Cardiac Amyloidosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Fondazione Toscana Gabriele Monasterio

Study on the Safety and Tolerability of Lixudebart and Rituximab for Patients with Rapidly Progressive Glomerulonephritis Due to ANCA-Associated Vasculitis

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Lixudebart
  • Sponsor:Alentis Therapeutics AG

Study on Nipocalimab for Children Aged 2-17 with Generalized Myasthenia Gravis

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Crohn's disease

Recruiting

Study on INTESTIFIX for Maintaining Remission in Children and Adults with Crohn's Disease After Exclusive Enteral Nutrition Treatment

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Intestifix
  • Sponsor:Klinikum der Universitaet Muenchen AöR
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Filgrastim
  • Sponsor:Universitair Medisch Centrum Utrecht

Anal fistula+1

Recruiting

Study on Gallium (68Ga) Chloride for Early Healing of Perianal Crohn's Disease Fistulas in Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Gallium (68GA) chloride
  • Sponsor:Amsterdam UMC Stichting

Study on the Effects of Annual vs. Semi-Annual Ocrelizumab Infusions in Patients with Active Multiple Sclerosis After 2 Years of Initial Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Fondation A De Rothschild

Study on Atopic Dermatitis Treatment with Baricitinib, Tralokinumab, Abrocitinib, Upadacitinib, and Dupilumab for Patients Needing Second-Line Systemic Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abrocitinib
  • Sponsor:Hospital Universitario La Paz

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.